CD11b (D12) BV605

BD® CD11b (D12) BV605

Name: CD11b (D12) BV605
Brand: BD®
SKU: 664449

Clone D12

(CE_IVD)

Spectrum Viewer

Protocol Library

Scientific Resources

Product Details

Brand: BD®

Reactivity: Human

Isotype: Mouse BALB/c IgG2a, κ

Immunogen: Human peripheral blood T lymphocytes

Vol. Per Test: 5 µl

Regulatory Status: CE_IVD

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed.

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

Product Notices

This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.

664449 Rev. 1

Antibody Details

D12

664449 Rev. 1

Format Details

BV605

The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.

Format: BV605

Excitation Source: Violet 405 nm

Excitation Max: 407 nm

Emission Max: 605 nm

664449 Rev.1

Citations & References

View product citations for antibody "664449" on CiteAb

Development References (20)

Lanier LL, Phillips JH. A map of the cell surface antigens expressed on resting and activated human natural killer cells. In: Reinherz EL. Ellis L. Reinherz .. et al., ed. Leukocyte typing II. New York: Springer-Verlag; 1986:157-170.
Aires A, Teixeira MDA, Lau C, et al. A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer".. BMC Hematol. 2018; 18:6. View Reference
Amirghofran Z, Zakerinia M, Shamseddin A. Significant association between expression of the CD11b surface molecule and favorable outcome for patients with acute myeloblastic leukemia.. Int J Hematol. 2001; 73(4):502-506. View Reference
Bernstein ID, Self S. Joint report of the Myeloid Section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human Myeloid and Hematopoietic Cells. New York, NY: Springer-Verlag; 1986:1-25.
Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Available: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html March 12, 2019. View Reference
Churchill HRO, Fuda FS, Xu J, et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.. Cytometry B Clin Cytom. 2021; 100(4):476-487. View Reference
Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells. In: CLSI. CLSI, ed. CLSI document H43-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2007:1-81. View Reference
Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens, 7th ed. In: CLSI. CLSI, ed. CLSI document GP41-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2017:1-85. View Reference
Clinical and Laboratory Standards Institute. Interference Testing in Clinical Chemistry: Approved Guidelines. Second Edition. In: CLSI. CLSI, ed. CLSI document EP07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005:1-12.
Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia.. Cytometry B Clin Cytom. 2011; 80(4):221-9. View Reference
Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
Kroll MH. Evaluating interference caused by lipemia.. Clin Chem. 2004; 50(11):1968-9. View Reference
Nikolac N. Lipemia: causes, interference mechanisms, detection and management.. Biochem Med (Zagreb). 2014; 24(1):57-67. View Reference
Repo H, Jansson SE, Leirisalo-Repo M. Anticoagulant selection influences flow cytometric determination of CD11b upregulation in vivo and ex vivo.. J Immunol Methods. 1995; 185(1):65-79. View Reference
Rizzatti EG, Garcia AB, Portieres FL, Silva DE, Martins SL, Falcão RP. Expression of CD117 and CD11b in bone marrow can differentiate acute promyelocytic leukemia from recovering benign myeloid proliferation.. Am J Clin Pathol. 2002; 118(1):31-7. View Reference
Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996; 10:877-895.
Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.. Am J Clin Pathol. 2009; 132(6):940-9. View Reference
Shalekoff S, Page-Shipp L, Tiemessen CT. Effects of anticoagulants and temperature on expression of activation markers CD11b and HLA-DR on human leukocytes.. Clin Diagn Lab Immunol. 1998; 5(5):695-702. View Reference
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230.
Zola H. CD10 Workshop Panel report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:505-507.

View All (20)

664449 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.